Time trends in antiretroviral treatment use in Australia, 1997-2000

Venereology

Volumn 14, Issue 4, 2001, Pages 162-168

  Rooney, P ^a   Taylor, S ^a   Couldwell, D ^a   Austin, D ^a   Block, M ^a   Quan, D ^a   Gowers, A ^a   O'Connor, C ^a   Gorton, C ^a   Allen, D ^a   Mulhall, B ^a   Mutimer, K ^a   Smith, D ^a,a   Keeffe, N ^a   Cooper, D ^a   Carr, A ^a   Miller, J ^a   Finlayson, R ^a   Wheatley, D ^a   Ellis, D ^a   Baker, D ^a   Kidd, J ^a   McFarlane, R ^a   Liang, M T ^a   Brown, K ^a   Petoumenos, K ^a   Law, M ^a   Huffam, S ^a   Savage, J ^a   Morgan, S ^a   Knibbs, P ^a   Sowden, D ^a   Rawlinson, M ^a   Walker, A ^a   Orth, D ^a   Lister, G ^a   Chuah, J ^a   Fankhauser, W ^a   Dickson, B ^a   Bradford, D ^a   Wilson, C ^a   Ree, H ^a   Magon, H ^a   Fairley, C K ^a   Roth, N ^a   Eu, B ^a   Strecker, S ^a   Russel, D ^a   Wood, H ^a   Mijch, A ^a   Hoy, J ^a   Pierce, A ^a   McCormack, C ^a   Watson, K ^a   Anderson, J ^a   Moore, R ^a   Russell, D ^a   McGovern, G ^a   McNair, R ^a   Bal, J ^a   Medland, N ^a   Daye, J ^a   Mallal, S ^a   French, M ^a   Skett, J ^a   Moore, C ^a   Maxwell, D ^a   Cain, A ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; CLINICAL OBSERVATION; CONTROLLED STUDY; DATA BASE; DRUG INFORMATION; DRUG USE; FETUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH;

EID: 0035669923     PISSN: 10321012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. HIV disease progression in Australia in the time of combination antiretroviral therapies
2. Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection
3. Use HIV protease inhibitors as pharmacoenhancers
4. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
6. A syndrome of lipoatrophy, lactic academia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
7. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
8. Structured treatment interruption in HIV infection
9. Immune control of HIV-1 after early treatment of acute infection
10. Virological and immunological effects of treatment interruption in HIV-1 infected patients with treatment failure
11. Trends in antiretroviral treatment for people with HIV in Australia: An observational database pilot study
12. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
13. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
14. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression